8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Validating the doubly weighted genetic risk score for the prediction of type 2 diabetes in the Lifelines and Estonian Biobank cohorts

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As many cases of type 2 diabetes (T2D) are likely to remain undiagnosed, better tools for early detection of high‐risk individuals are needed to prevent or postpone the disease. We investigated the value of the doubly weighted genetic risk score (dwGRS) for the prediction of incident T2D in the Lifelines and Estonian Biobank (EstBB) cohorts. The dwGRS uses an additional weight for each single nucleotide polymorphism in the risk score, to correct for “Winner's curse” bias in the effect size estimates. The traditional (single‐weighted genetic risk score; swGRS) and dwGRS were calculated for participants in Lifelines ( n = 12,018) and EstBB ( n = 34,129). The dwGRS was found to have stronger association with incident T2D (hazard ratio [HR] = 1.26 [95% confidence interval: 1.10–1.43] and HR = 1.35 [1.28–1.42]) compared to the swGRS (HR = 1.21 [1.07–1.38] and HR = 1.25 [1.19–1.32]) in Lifelines and EstBB, respectively. Comparing the 5‐year predicted risks from the models with and without the dwGRS, the continuous net reclassification index was 0.140 (0.034–0.243; p = .009 Lifelines), and 0.257 (0.194–0.319; p < 2 × 10 −16 EstBB). The dwGRS provided incremental value to the T2D prediction model with established phenotypic predictors. It clearly distinguished the risk groups for incident T2D in both biobanks thereby showing its clinical relevance.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

          Glucose metabolism is normally regulated by a feedback loop including islet β cells and insulin-sensitive tissues, in which tissue sensitivity to insulin affects magnitude of β-cell response. If insulin resistance is present, β cells maintain normal glucose tolerance by increasing insulin output. Only when β cells cannot release sufficient insulin in the presence of insulin resistance do glucose concentrations rise. Although β-cell dysfunction has a clear genetic component, environmental changes play an essential part. Modern research approaches have helped to establish the important role that hexoses, aminoacids, and fatty acids have in insulin resistance and β-cell dysfunction, and the potential role of changes in the microbiome. Several new approaches for treatment have been developed, but more effective therapies to slow progressive loss of β-cell function are needed. Recent findings from clinical trials provide important information about methods to prevent and treat type 2 diabetes and some of the adverse effects of these interventions. However, additional long-term studies of drugs and bariatric surgery are needed to identify new ways to prevent and treat type 2 diabetes and thereby reduce the harmful effects of this disease. Copyright © 2014 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

            Appropriate quantification of added usefulness offered by new markers included in risk prediction algorithms is a problem of active research and debate. Standard methods, including statistical significance and c statistic are useful but not sufficient. Net reclassification improvement (NRI) offers a simple intuitive way of quantifying improvement offered by new markers and has been gaining popularity among researchers. However, several aspects of the NRI have not been studied in sufficient detail. In this paper we propose a prospective formulation for the NRI which offers immediate application to survival and competing risk data as well as allows for easy weighting with observed or perceived costs. We address the issue of the number and choice of categories and their impact on NRI. We contrast category-based NRI with one which is category-free and conclude that NRIs cannot be compared across studies unless they are defined in the same manner. We discuss the impact of differing event rates when models are applied to different samples or definitions of events and durations of follow-up vary between studies. We also show how NRI can be applied to case-control data. The concepts presented in the paper are illustrated in a Framingham Heart Study example. In conclusion, NRI can be readily calculated for survival, competing risk, and case-control data, is more objective and comparable across studies using the category-free version, and can include relative costs for classifications. We recommend that researchers clearly define and justify the choices they make when choosing NRI for their application. Copyright © 2010 John Wiley & Sons, Ltd.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Genomics, type 2 diabetes, and obesity.

                Bookmark

                Author and article information

                Contributors
                k.parna@umcg.nl
                Journal
                Genet Epidemiol
                Genet. Epidemiol
                10.1002/(ISSN)1098-2272
                GEPI
                Genetic Epidemiology
                John Wiley and Sons Inc. (Hoboken )
                0741-0395
                1098-2272
                14 June 2020
                September 2020
                : 44
                : 6 ( doiID: 10.1002/gepi.v44.6 )
                : 589-600
                Affiliations
                [ 1 ] Department of Epidemiology University of Groningen, University Medical Center Groningen Groningen The Netherlands
                [ 2 ] Institute of Genomics University of Tartu Tartu Estonia
                [ 3 ] Institute of Mathematics and Statistics University of Tartu Tartu Estonia
                Author notes
                [*] [* ] Correspondence

                Katri Pärna, Department of Epidemiology, University Medical Center Groningen, Groningen, the Netherlands and Institute of Genomics, University of Tartu, 9700 RB Groningen, Tartu, Estonia.

                Email: k.parna@ 123456umcg.nl

                Author information
                http://orcid.org/0000-0002-0013-6077
                Article
                GEPI22327
                10.1002/gepi.22327
                7496366
                80d4232f-f2ee-40e7-906c-6d3d13b3a5ca
                © 2020 The Authors. Genetic Epidemiology Published by Wiley Periodicals LLC

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 17 February 2020
                : 07 May 2020
                : 22 May 2020
                Page count
                Figures: 2, Tables: 3, Pages: 12, Words: 8116
                Funding
                Funded by: Netherlands Organization of Scietific Research NWO
                Award ID: 175.010.2007.006
                Funded by: Estonian Research Council , open-funder-registry 10.13039/501100002301;
                Award ID: GP1GV9353
                Award ID: IUT20‐60
                Funded by: Centre of Excellence for Genomics and Translational Medicine (GENTRANSMED)
                Funded by: the University of Tartu (SP1GVARENG) , open-funder-registry 10.13039/501100007821;
                Funded by: Archimedes Foundation , open-funder-registry 10.13039/100008369;
                Award ID: 3.2.1001.11‐0033
                Funded by: EU 2020
                Award ID: 692145
                Funded by: European Regional Development Fund , open-funder-registry 10.13039/501100008530;
                Award ID: 2014‐2020.4.01.16‐0024
                Funded by: Horizon 2020 , open-funder-registry 10.13039/100010661;
                Award ID: 777107‐PRESICE4Q
                Funded by: Estonian Research Council , open-funder-registry 10.13039/501100002301;
                Award ID: PUT PRG687
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                September 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.0 mode:remove_FC converted:11.09.2020

                Public health
                genetic risk score,incidence,personalized prediction,type 2 diabetes
                Public health
                genetic risk score, incidence, personalized prediction, type 2 diabetes

                Comments

                Comment on this article